Potential impact of antiviral drug use during influenza pandemic

Emerging Infectious Diseases

Volumn 11, Issue 9, 2005, Pages 1355-1362

  Gani, Raymond ^a   Hughes, Helen ^a   Fleming, Douglas ^b   Griffin, Thomas ^a   Medlock, Jolyon ^a   Leach, Steve ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; AVIAN INFLUENZA; EPIDEMIC; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFLUENZA; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT OUTCOME; VIRUS STRAIN;

EID: 23944479368     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1209.041344     Document Type: Article

References (30)

1. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002;76:105-15.
2. Nguyen-Van-Tarn JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine. 2003;21:1762-8.
3. World Health Organization. Influenza pandemic plan. The role of WHO and guidelines for national and regional planning. Geneva: The Organization; 1999.
4. Patriarca PA, Cox NJ. Influenza pandemic preparedness plan for the United States. J Infect Dis. 1997;176(Suppl 1):S4-7.
5. UK Department of Health. UK pandemic influenza contingency plan. March 2005 [cited 2005 Mar 1]. Available from http://www.dh.gov.uk/assetRoot/04/10/44/ 37/04104437.pdf
6. Fock R, Bergmann H, Bußmann H, Fell G, Finke E-J, Koch U, et al. Influenza pandemic: preparedness planning in Germany. Eurosurveillance. 2002;7:1-5.
7. Health Canada. Canadian Pandemic Influenza Plan, Health Canada; 2004. [cited 2005 Mar 1]. Available from http://www.phac-aspc.gc.ca/cpip-pclcpi/
8. Webby RJ, Webster RG. Are we ready for pandemic influenza? Science. 2003;302:1519-22.
9. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis. 2003;36:1552-61.
10. Pang X, Zu Z, Xu F, Guo J, Gong X, Liu D, et al. Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing, 2003. JAMA. 2003;290:3215-21.
11. Wainright PO, Perdue ML, Brugh M, Beard CW. Amantadine resistance among hemagglutinin subtype 5 strains of avian influenza virus. Avian Dis. 1991;35:31-9.
12. National Institute for Clinical Excellence. Full guidance on the use of zanamivir, National Institute for Clinical Excellence. Full guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza. Available from http://www.nice.org.uk/pdf/58_Flu_full-guidance.pdf (2005)
13. Stiver G. The treatment of influenza with antiviral drugs. CMAJ. 2003;168:49-57.
14. Kiso M. Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-65.
15. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47:2264-72.
16. Balicer RD, Huerta M, Grotto I. Tackling the next influenza pandemic. BMJ. 2004;328:1391-2.
17. Nguyen-Van-Tam JS, Leach SA, Cooper B, Gani R, Goddard NJ, Watson JM, et al. Tackling the next influenza pandemic: ring prophylaxis may prove useful early on, but is unlikely to be effective or practical to implement once the pandemic is established. BMJ. Epub 2004 July 22 [cited 2005 Mar 1]. Available from http://bmj.bmjjournals. com/cgi/eletters/328/7453/1391#68042.
18. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659-71.
19. Longini IM, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623-33.
20. Genugten ML, Heijnen ML, Jager JC. Pandemic influenza and healthcare demand in the Netherlands: scenario analysis. Emerg Infect Dis. 2003;9:531-8.
21. Cauchemez S, Carrat F, Viboud C, Valleron AJ, Boelle PY. A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. Stat Med. 2004;23:3469-87.
22. Fleming D, Charlton J, McCormick A. The population at risk in relation to influenza immunisation policy in England and Wales. Health Trends. 1997;29:42-7.
23. Department of Health. Influenza immunisation. CMO's update. 1997. [cited 2005 Mar 1]. Available from www.dh.gov.uk/assetRoot/04/01/35/74/04013574.pdf
24. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med. 1987;82:20-6.
25. Mann PG, Pereira MS, Smith JW, Hart RJ, Williams WO. A five-year study of influenza in families. Joint Public Health Laboratory Service/Royal College of General Practitioners Working Group. J Hyg(Lond). 1981;87:191-200.
26. The influenza epidemic in England and Wales 1957-58. Reports on public health and medical subjects no. 100. London: Her Majesty's Stationary Office; 1960.
27. Taylor MP. Influenza 1968-1970 incidence in general practice based on a population survey. Journal of the Royal College of General Practitions. 1971;21:17-22.
28. Reports on public health and medical subjects no. 4: report on the pandemic of influenza 1918-19. London: Her Majesty's Stationary Office; 1920.
29. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol. 1980;112:798-811.
30. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature. 2004;432:904-6.